Commemorating 25 years of fighting pancreatic cancer
Learn More

Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • COVID-19 Resources
    • News →
      • Latest News
      • Research News
      • Foundation News
      • UCLA Activity Summary Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Caregivers
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Financial Aid
    • Resources →
      • Symptom Management Workbook
      • Guidelines for Patients: Pancreatic Cancer
      • Creating Your Health Care Team
      • A Virtual Advocate
      • Patient Tools
  • HOW YOU CAN HELP
    • You Can Help Funds
    • Host Your Own Event
    • Event Calendar
    • Get Inspired
    • November Awareness Month →
      • World Pancreatic Cancer Day
    • Other Ways to Give →
      • Shop Online Store
      • Wedding Program
      • Volunteer
      • Planned Giving
      • Car Program
  • SEARCH
Home / Research / Seed Grant Program / Seed Grant Recipients / Nancy Klauber-DeMore, MD

Nancy Klauber-DeMore, MD

Nancy Klauber-DeMore, MD
Nancy Klauber-DeMore, MD
Professor of Surgery

Surgery

Medical University of South Carolina
Charleston, SC

Evaluation of Novel Targeted Therapy to Secreted Frizzled Related Protein 2 in Pancreatic Cancer

Overview

Aim: Therapy

Pancreatic cancer remains a leading cause of cancer deaths in the United States. Even with improved chemotherapy regimens, five-year survival remains dismally at just around 10%. One of the barriers to treatment in pancreatic cancer is its desmoplastic stroma. Pancreatic cancer has the highest level of stroma of any solid organ tumor at about 80% of its mass, which decreases the tumor vasculature and raises the interstitial pressure – conditions that shield the tumor from chemotherapy and the immune response.

Secreted frizzled related-protein 2 (SFRP2) is a glycoprotein that has been shown to be
upregulated in multiple cancer types. It has previously been shown to stimulate angiogenesis, stimulate tumor growth, and upregulate markers of immune dysfunction. Our preliminary data shows that SFRP2 is highly expressed in pancreatic cancer and is prognostic for survival. We have also shown that SFRP2 and is associated with tumor fibrosis and stimulates collagen production and EMT in fibroblasts. Further, we have developed a humanized monoclonal antibody to SFRP2 (hSFRP2 mAb) that has shown efficacy in inhibiting tumor growth, angiogenesis, and overcoming resistance to PD-1 inhibition. Due to pancreatic cancer’s high stromal content, we hypothesized that SFRP2 may play a larger role in this tumor type and may be a mechanism by which fibroblasts in the tumor stroma become activated and develop a myofibroblast phenotype. Based on the multiple cell types that SFRP2 effects in tumor growth, we hypothesize that the hSFRP2 mAb will inhibit pancreatic cancer growth as monotherapy, and will be synergistic with chemotherapy and immunotherapy.

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Contact Us